BACKGROUND: Interferon-gamma (IFN-gamma) assays are new tests for tuberculosis (TB) infection, and T-cell responses may be correlated with antigen burden. However, it is unclear if IFN-gamma assays can be used to monitor response to TB treatment. MATERIALS AND METHODS: We measured T-cell responses to TB specific antigens in 60 Indian patients with microbiologically confirmed active pulmonary tuberculosis, before, during, and after TB treatment. Most patients were hospitalized and had moderate to advanced disease. IFN-gamma responses were measured using the commercial whole-blood Quanti-FERON-TB Gold In Tube (QFT-G) assay at three time-points: at diagnosis (N = 60), after 2 months of intensive treatment (N = 47), and at 6 months (treatment completion) (N = 39). RESULTS: At baseline, 44 of 60 (73%) patients were positive by QFT-G. At the second time-point, 38 of 47 (81%) patients were positive. At treatment completion, 31 of 39 (79%) patients were positive. Changes in IFN-gamma responses over time were highly inconsistent--some individuals showed increases, while others showed decreases or no changes. Although the average IFN-gamma levels decreased slightly during treatment (not significant), the QFT-G sensitivity remained mostly unchanged during therapy. CONCLUSIONS: Our data suggest that the QFT-G assay has modest sensitivity in patients with moderate to advanced pulmonary disease, but our results do not show a clear correlation between antigen burden and T-cell responses. Further research is needed to understand the kinetics of T-cell responses during TB treatment.
BACKGROUND:Interferon-gamma (IFN-gamma) assays are new tests for tuberculosis (TB) infection, and T-cell responses may be correlated with antigen burden. However, it is unclear if IFN-gamma assays can be used to monitor response to TB treatment. MATERIALS AND METHODS: We measured T-cell responses to TB specific antigens in 60 Indian patients with microbiologically confirmed active pulmonary tuberculosis, before, during, and after TB treatment. Most patients were hospitalized and had moderate to advanced disease. IFN-gamma responses were measured using the commercial whole-blood Quanti-FERON-TB Gold In Tube (QFT-G) assay at three time-points: at diagnosis (N = 60), after 2 months of intensive treatment (N = 47), and at 6 months (treatment completion) (N = 39). RESULTS: At baseline, 44 of 60 (73%) patients were positive by QFT-G. At the second time-point, 38 of 47 (81%) patients were positive. At treatment completion, 31 of 39 (79%) patients were positive. Changes in IFN-gamma responses over time were highly inconsistent--some individuals showed increases, while others showed decreases or no changes. Although the average IFN-gamma levels decreased slightly during treatment (not significant), the QFT-G sensitivity remained mostly unchanged during therapy. CONCLUSIONS: Our data suggest that the QFT-G assay has modest sensitivity in patients with moderate to advanced pulmonary disease, but our results do not show a clear correlation between antigen burden and T-cell responses. Further research is needed to understand the kinetics of T-cell responses during TB treatment.
Authors: J Y Lee; H J Choi; I-N Park; S-B Hong; Y-M Oh; C-M Lim; S D Lee; Y Koh; W S Kim; D S Kim; W D Kim; T S Shim Journal: Eur Respir J Date: 2006-04-12 Impact factor: 16.671
Authors: Keertan Dheda; Zarir F Udwadia; Jim F Huggett; Margaret A Johnson; Graham A W Rook Journal: Curr Opin Pulm Med Date: 2005-05 Impact factor: 3.155
Authors: J Vekemans; C Lienhardt; J S Sillah; J G Wheeler; G P Lahai; M T Doherty; T Corrah; P Andersen; K P McAdam; A Marchant Journal: Infect Immun Date: 2001-10 Impact factor: 3.441
Authors: Madhukar Pai; Kaustubh Gokhale; Rajnish Joshi; Sandeep Dogra; Shriprakash Kalantri; Deepak K Mendiratta; Pratibha Narang; Charles L Daley; Reuben M Granich; Gerald H Mazurek; Arthur L Reingold; Lee W Riley; John M Colford Journal: JAMA Date: 2005-06-08 Impact factor: 56.272
Authors: Clare R Sander; Ansar A Pathan; Natalie E R Beveridge; Ian Poulton; Angela Minassian; Nicola Alder; Johan Van Wijgerden; Adrian V S Hill; Fergus V Gleeson; Robert J O Davies; Geoffrey Pasvol; Helen McShane Journal: Am J Respir Crit Care Med Date: 2009-01-16 Impact factor: 21.405
Authors: Tom G Connell; Mary-Ann Davies; Christine Johannisen; Kathryn Wood; Sandy Pienaar; Katalin A Wilkinson; Robert J Wilkinson; Heather J Zar; David Beatty; Mark P Nicol; Nigel Curtis; Brian Eley Journal: BMC Infect Dis Date: 2010-05-27 Impact factor: 3.090
Authors: Martine G Aabye; Pernille Ravn; George PrayGod; Kidola Jeremiah; Apolinary Mugomela; Maria Jepsen; Daniel Faurholt; Nyagosya Range; Henrik Friis; John Changalucha; Aase B Andersen Journal: PLoS One Date: 2009-01-19 Impact factor: 3.240